

CADISS GP LETTER

Title of Project: Cervical Artery Dissection in Stroke Study (CADISS)

Centre Number: 5201

Patient Identification Number for this trial:

N	N	N
---	---	---

 - 11 -

Y	Y
---	---

 -

E	E
---	---

For non-randomised patients only

Chief Investigators: Professor JW Norris/Professor HS Markus

GP Name:		TREATMENT GROUP	
GP Address:		ANTIPLATELET*	ANTICOAGULANT*
		Drug:	Drug:
		Dose:	Dose:
GP Postcode:		*please delete as appropriate	
GP Fax:			

Patient Name:		Patient DOB:	DD / MM / YYYY
Patient Address:		Patient Hosp No.	
Postcode:			

Consultant in Charge of Patient Care:	
Consultant Contact Number:	

Your patient was recently admitted to hospital with a **stroke and/or TIA and/or Horner's syndrome and/or neck pain*** attributed to cervical artery dissection. He/she has been recruited to the **randomised/non-randomised*** group (***please delete as appropriate**) of the Cervical Artery Dissection in Stroke Study (CADISS). This is a prospective, multicentre, randomised study comparing antiplatelet treatment to anticoagulants in the treatment of acute cervical artery dissection. Information is also being collected on patients ineligible for randomisation (non-randomised patients).

Anticoagulants and antiplatelet agents are routinely used to prevent further stroke in patients with cervical artery dissection, but there is no evidence based data to justify their use. The patient will be on the treatment for a period of 3 to 6 months depending on the follow up imaging which will be performed by the team looking after the patient.